Side firing Neodymium:Yag laser prostatectomy: Six years of experience with 170 patients


Metin A., Kayigil Ö., Ahmed S. I.

International Urology and Nephrology, vol.35, no.1, pp.33-36, 2003 (Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 1
  • Publication Date: 2003
  • Doi Number: 10.1023/a:1025948028530
  • Journal Name: International Urology and Nephrology
  • Journal Indexes: Scopus
  • Page Numbers: pp.33-36
  • Keywords: Benign prostate hyperplasia, Laser prostatectomy
  • Ankara Yıldırım Beyazıt University Affiliated: No

Abstract

Objectives: To evaluate the results and complications in 170 patients with symptomatic benign hyperplasia who underwent laser prostatectomy focusing on six month and long-term results. Methods: A total of 170 patients underwent side firing Neodymium:Yag laser prostatectomy between January 1995 and February 2001 of whom 152 and 82 were available after 6 months and 3 years follow-up respectively. Evaluations were done by American Urological Association (AUA) symptom score, peak urinary flow rate, residual volumes and immediate and long-term complications were assessed. Results: Median patient follow-up period was 34.1 months (16-70). After 6 months the mean AUA score reduced from 20.2 to 8.2 and found as 9.4 in patients who completed 3 years follow-up. Post voiding urine volume decreased from 110 ml to 46 ml at 6 months and found as 60 ml after 3 years. Peak urinary flow rate increased from 3.4 to 16.4 ml per second after 6 months and found as 14.8 ml per second after 3 years. The overall complications of 170 patients in early period included urinary retention after catheter removal in 6 (3.52%), early bleeding in 2 (1.17%), late bleeding in 1 (0.58%). Late complications included urethral stricture requiring internal urethrotomy in 12 (7.8%), bladder neck contracture in 4 (2.6%) and repeated laser prostatectomy after 2 years in 10 (5.88%) patients. Conclusion: Side firing Neodymium:Yag laser prostatectomy offers a safe and effective treatment for bladder outlet obstruction due to benign hyperplasia with minimal associated morbidity.